AIRLINK 150.25 Increased By ▲ 13.66 (10%)
BOP 10.12 Increased By ▲ 1.00 (10.96%)
CNERGY 7.42 Increased By ▲ 1.00 (15.58%)
CPHL 71.13 Increased By ▲ 6.47 (10.01%)
FCCL 45.71 Increased By ▲ 4.16 (10.01%)
FFL 14.34 Increased By ▲ 1.30 (9.97%)
FLYNG 37.15 Increased By ▲ 3.38 (10.01%)
HUBC 138.35 Increased By ▲ 12.58 (10%)
HUMNL 12.40 Increased By ▲ 1.00 (8.77%)
KEL 4.56 Increased By ▲ 0.55 (13.72%)
KOSM 4.99 Increased By ▲ 1.00 (25.06%)
MLCF 69.65 Increased By ▲ 6.33 (10%)
OGDC 203.01 Increased By ▲ 18.46 (10%)
PACE 5.38 Increased By ▲ 0.96 (21.72%)
PAEL 44.24 Increased By ▲ 4.02 (10%)
PIAHCLA 13.45 Increased By ▲ 1.22 (9.98%)
PIBTL 8.62 Increased By ▲ 1.00 (13.12%)
POWER 14.96 Increased By ▲ 1.09 (7.86%)
PPL 152.75 Increased By ▲ 13.89 (10%)
PRL 27.02 Increased By ▲ 2.46 (10.02%)
PTC 19.29 Increased By ▲ 1.75 (9.98%)
SEARL 75.06 Increased By ▲ 6.82 (9.99%)
SSGC 30.46 Increased By ▲ 2.77 (10%)
SYM 13.95 Increased By ▲ 1.27 (10.02%)
TELE 6.93 Increased By ▲ 0.99 (16.67%)
TPLP 8.00 Increased By ▲ 1.00 (14.29%)
TRG 61.90 Increased By ▲ 5.63 (10.01%)
WAVESAPP 8.94 Increased By ▲ 1.00 (12.59%)
WTL 1.31 Increased By ▲ 0.15 (12.93%)
YOUW 3.75 Increased By ▲ 0.54 (16.82%)
AIRLINK 150.25 Increased By ▲ 13.66 (10%)
BOP 10.12 Increased By ▲ 1.00 (10.96%)
CNERGY 7.42 Increased By ▲ 1.00 (15.58%)
CPHL 71.13 Increased By ▲ 6.47 (10.01%)
FCCL 45.71 Increased By ▲ 4.16 (10.01%)
FFL 14.34 Increased By ▲ 1.30 (9.97%)
FLYNG 37.15 Increased By ▲ 3.38 (10.01%)
HUBC 138.35 Increased By ▲ 12.58 (10%)
HUMNL 12.40 Increased By ▲ 1.00 (8.77%)
KEL 4.56 Increased By ▲ 0.55 (13.72%)
KOSM 4.99 Increased By ▲ 1.00 (25.06%)
MLCF 69.65 Increased By ▲ 6.33 (10%)
OGDC 203.01 Increased By ▲ 18.46 (10%)
PACE 5.38 Increased By ▲ 0.96 (21.72%)
PAEL 44.24 Increased By ▲ 4.02 (10%)
PIAHCLA 13.45 Increased By ▲ 1.22 (9.98%)
PIBTL 8.62 Increased By ▲ 1.00 (13.12%)
POWER 14.96 Increased By ▲ 1.09 (7.86%)
PPL 152.75 Increased By ▲ 13.89 (10%)
PRL 27.02 Increased By ▲ 2.46 (10.02%)
PTC 19.29 Increased By ▲ 1.75 (9.98%)
SEARL 75.06 Increased By ▲ 6.82 (9.99%)
SSGC 30.46 Increased By ▲ 2.77 (10%)
SYM 13.95 Increased By ▲ 1.27 (10.02%)
TELE 6.93 Increased By ▲ 0.99 (16.67%)
TPLP 8.00 Increased By ▲ 1.00 (14.29%)
TRG 61.90 Increased By ▲ 5.63 (10.01%)
WAVESAPP 8.94 Increased By ▲ 1.00 (12.59%)
WTL 1.31 Increased By ▲ 0.15 (12.93%)
YOUW 3.75 Increased By ▲ 0.54 (16.82%)
BR100 12,402 Increased By 1161.5 (10.33%)
BR30 35,560 Increased By 3425.8 (10.66%)
KSE100 117,298 Increased By 10123.1 (9.45%)
KSE30 35,839 Increased By 3190.7 (9.77%)

NEW DELHI: India currently has no plans to give booster doses as some nations have begun doing, the government's chief Covid-19 advisor said Wednesday as the country nears the milestone of one billion vaccine injections.

Doctor Vinod K. Paul said meanwhile with the country's vaccine makers ramping up production and domestic needs diminishing, India should be able to resume being a major exporter of jabs from next year.

More than 15 countries worldwide have begun issuing third doses of coronavirus vaccines to older citizens, including in Israel and in European Union nations such as France, Italy and Germany.

But Paul, part of the Indian government's advisory body NITI Aayog, said there is no clear guidance on whether a third dose is necessary, including from the World Health Organization.

"As of now we do not have a recommendation for a booster bump-up dose," Paul told reporters, adding however that the government would "continue to watch this space very carefully".

His comments came with the number of vaccine doses administered in India set to hit one billion in the coming days, with some 75 percent of those eligible receiving one shot and around 30 percent double vaccinated.

WHO says countries should not order COVID-19 boosters while others still need vaccines

India is the world's largest vaccine producer but the country halted exports of Covid jabs earlier this year to focus on its domestic needs after a devastating infections surge overwhelmed hospitals.

But with vaccination rates now high and coronavirus cases down sharply, exports have resumed in recent days, with a total of around four million doses reportedly being sent to Nepal, Bangladesh, Myanmar and Iran.

Production of Covishield -- the Indian-made version of the AstraZeneca vaccine -- and the homegrown Covaxin is currently around 250 million shots per month and is on course to reach 270 million soon, according to officials.

Combined with the production of other vaccines made in India -- including Johnson & Johnson with local partner Biological E -- coming on line, the country could begin exporting again on a large scale next year.

"Huge, huge availability can be visualised potentially," Paul said, allowing India -- a vital supplier to other low-income countries -- to be "potentially very generous" again in 2022.

Comments

Comments are closed.